Prognosis
Remdesivir Gets Lukewarm Endorsement From Experts in Covid Fight
- Trials of remdesivir have had limitations, journal says
- Panel calls for more study of Gilead drug in Covid patients
This article is for subscribers only.
Gilead Sciences Inc.’s remdesivir is worth prescribing for patients with severe Covid-19 though evidence of its benefits remains inconclusive, according to a panel of international experts convened by the British Medical Journal.
The effectiveness of most interventions with remdesivir is uncertain because most of the trials so far have been small and have limitations, the authors said in a review for the journal.